New technique developed at Washington University in St. Louis uses blood test
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test.
Hong Chen, a biomedical engineer, and Eric C. Leuthardt, MD, a neurosurgeon, led a team of engineers, physicians and researchers who have developed a groundbreaking, proof-of-concept technique that allows biomarkers from a brain tumor to pass through the tough blood-brain barrier into a patient’s blood using noninvasive focused ultrasound and some tiny bubbles, potentially eliminating the need for a surgical biopsy.
Chen, assistant professor of biomedical engineering in the School of Engineering & Applied Science and of radiation oncology in the School of Medicine, said while researchers have already learned how to get a drug through the blood-brain barrier into the brain via the bloodstream, no one — until now — has found a way to release tumor-specific biomarkers — in this case, messenger RNA (mRNA)— from the brain into the blood.
“I see a clear path for the clinical translation of this technique,” said Chen, an expert in ultrasound technology. “Blood-based liquid biopsies have been used in other cancers, but not in the brain. Our proposed technique may make it possible to perform a blood test for brain cancer patients.”
The blood test would reveal the amount of mRNA in the blood, which gives physicians specific information about the tumor that can help with diagnosis and treatment options.
Results of the study, which blends imaging, mechanobiology, genomics, immunology, bioinformatics, oncology, radiology and neurosurgery, are published in Scientific Reports April 26, 2018.
Chen; Leuthardt, professor of neurological surgery in the School of Medicine; and researchers from the Schools of Engineering & Applied Science and of Medicine, tested their theory in a mouse model using two different types of the deadly glioblastoma brain tumor. They targeted the tumor using focused ultrasound, a technique that uses ultrasonic energy to target tissue deep in the body without incisions or radiation. Similar to a magnifying glass that can focus sunlight to a tiny point, focused ultrasound concentrates ultrasound energy to a tiny point deep into the brain.
Once they had the target — in this case, the brain tumor — researchers then injected microbubbles that travel through the blood similar to red blood cells. When the microbubbles reached the target, they popped, causing tiny ruptures of the blood-brain barrier that allows the biomarkers from the brain tumor to pass through the barrier and release into the bloodstream. A blood sample can determine the biomarkers in the tumor.
This technique could lead to personalized medicine.
“In many ways this has been a holy grail for brain tumor therapy,” Leuthardt said. “Having the ability to monitor the changing molecular events of the tumor in an ongoing way allows us to not only better diagnose a tumor in the brain, but to follow its response to different types of treatment.”
“Once the blood-brain barrier is open, physicians can deliver drugs to the brain tumor,” Chen said. “Physicians can also collect the blood and detect the expression level of biomarkers in the patient. It enables them to perform molecular characterizations of the brain tumor from a blood draw and guide the choice of treatment for individual patients.”
In addition, Gavin Dunn, MD, assistant professor of neurosurgery, a co-author and leader in cancer immunobiology, plans to use the technique with immunotherapy, which offers precision treatment that targets specific biomarkers in the brain.
“This noninvasive focused ultrasound-enabled liquid biopsy technique can be useful for long-term monitoring of brain cancer treatment response, where repeated surgical tissue biopsies may not be feasible,” Chen said. “Meanwhile, variations within tumors pose a significant challenge to cancer biomarker research. Focused ultrasound can precisely target different locations of the tumor, thereby causing biomarkers to be released in a spatially-localized manner and allow us to better understand the spatial variations of the tumor and develop better treatment.”
The team continues to work to refine the process. The future will require integration with advanced genomic sequencing and bioinformatics to enable even more refined diagnostics. These efforts are being led by co-authors Allegra Petti, assistant professor of medicine, and Xiaowei Wang, associate professor of radiation oncology.
“Our ongoing work is to optimize the technique and evaluate its sensitivity and safety,” Chen said.
Learn more: Noninvasive brain tumor biopsy on the horizon
The Latest on: Personalized medicine
[google_news title=”” keyword=”personalized medicine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized medicine
- Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Regionon May 7, 2024 at 8:56 am
Biocartis (Mechelen, Belgium) announced an expansion of its collaboration with Merck Serono Middle East and Merck Saudi Ltd., both affiliates of Merck KGaA (“Merck”). The collaboration aims to improve ...
- OM1 Launches Three New Products Powered by Patented AI Platform to Expedite Delivery of Personalized Medicineon May 6, 2024 at 6:00 am
OM1 Orion, OM1 Lyra, and OM1 Polaris powered by PhenOMTM – an artificial intelligence-powered digital phenotyping platform for personalized medicine and clinical research. OM1 is the leader in ...
- Can a personalized antibiotics, prebiotics, and probiotics combo help treat IBS?on May 4, 2024 at 11:00 pm
A pilot study suggests that a personalized combination of antibiotics, prebiotics, and probiotics may help treat the symptoms of post-infectious irritable bowel syndrome (IBS).
- Molecular Profiling and Companion Diagnostics: Where is Personalized Medicine in Cancer Heading?on May 4, 2024 at 5:00 pm
The goal of personalized medicine is to use the right drug at the right dose – with minimal or no toxicity – for the right patient at the right time. Recent advances in understanding cell ...
- 'Despite promise, personalized medicine for head and neck cancers facing hurdles'on April 26, 2024 at 3:45 am
Improved efficacy: By identifying specific mutations driving tumour growth, personalized medicine allows for targeted therapies that have a higher success rate compared to ‘one-size-fits-all’ ...
- AI could predict whether cancer treatments will work, experts say: ‘Exciting time in medicine'on April 23, 2024 at 3:00 am
A chemotherapy alternative called immunotherapy is showing promise in treating cancer — and a new artificial intelligence tool could help ensure that patients have the best possible experience.
- Personalized Medicine in Oncologyon April 17, 2024 at 5:00 pm
Current advances in the biology of cancer and emergence of new tools for genome analysis have opened clinical perspectives in oncology, generally termed as 'personalized medicine'. This broad term ...
- Readers respond to OTC antidepressants, personalized medicine, restoring trust in public health, and moreon April 12, 2024 at 5:00 pm
This essay supports my assertion that the fiscal issues that might hinder the usefulness of personalized medicine need to be dealt with at the same time as we continue our progress towards large ...
- Personalized medicine: We’re not there yeton April 4, 2024 at 5:00 pm
He predicted that in 10 years personalized medicine would allow physicians to employ “predictive genetic tests … so that each of us can learn of our individual risks for future illness and ...
via Bing News